- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
NCCN Congress: Hematologic Malignancies | Conferences
Assessing Risk for Optimal Treatment of High-Risk Polycythemia Vera in the Frontline Setting
October 18, 2022
During the NCCN 2022 Annual Congress: Hematologic Malignancies, Aaron Gerds, MD, explained risk stratification in patients with polycythemia vera, frontline treatment options, and outcomes for the patient population based on findings from clinical trials.
Brentuximab Vedotin Shows Promising Activity as First-Line Use in Classical Hodgkin Lymphoma
October 17, 2022
At the NCCN Annual Congress:Hematologic Malignancies, David J. Straus, MD debated if this was the best course of action for treating Hodgkin lymphoma.
Evaluating Effective Treatment Options and Strategies for Relapsed/Refractory Mantle Cell Lymphoma
October 15, 2022
At the 2022 NCCN annual congress, Tycel Phillips, MD, discussed different strategies that can be effective as second-line treatments in various patients who have relapsed/refractory mantle cell lymphoma.
New Options Shape the Treatment Landscape of ALL
October 15, 2022
Aaron Logan, MD, PhD, discusses some of the treatment options available for patients with acute lymphoblastic leukemia.
Utilizing Immunotherapy Treatments and Managing Toxicities in Multiple Myeloma
October 15, 2022
At a 2022 NCCN meeting, a panel discussed the use of immunotherapy for the treatment of patients with multiple myeloma, specifically how to choose the best course of action and how to manage toxicities.
Classification, Treatment, and Supportive Care Options in AML
October 14, 2022
At the 2022 NCCN: Hematologic Malignancies Conference, a panel discussion gave an overview of current treatment trends for acute myeloid leukemia, as well as supportive care measures to utilize during therapy.
Future Directions and Unmet Needs in T-ALL
October 14, 2022
Bijal Shah, MD, MS, discusses the unmet medical needs in the T-cell acute lymphoblastic leukemia space and what future research aims to examine.
Standard of Care in Newly Diagnosed Myeloma
October 19, 2021
Shaji Kumar, MD, a hematologist at the Mayo Clinic and chair of the Plasma Cell Disorders Scientific Committee at the American Society of Hematology, discuses the standard of care in newly diagnosed myeloma.
Treating Post-MPN Acute Leukemia Remains an Unmet Medical Need
October 18, 2021
In an interview with Targeted Oncology, Gabriela Hobbs, MD discussed the current treatment landscape for MPNs and the research that is aiming to address post-MPN acute leukemia and unmet needs for the patient population.
Improving Risk/Benefit of Frontline Classical Hodgkin Lymphoma Treatment
October 17, 2021
Many options exist for advanced stage cHL, with varying degrees of toxicity. Ranjana H. Advani, MD, gives an overview of each during a presentation at the NCCN 2021 Virtual Congress: Hematologic Malignancies.